Edition:
United Kingdom

Arbutus Biopharma Corp (ABUS.OQ)

ABUS.OQ on NASDAQ Stock Exchange Global Select Market

4.48USD
5:06pm GMT
Change (% chg)

$0.10 (+2.28%)
Prev Close
$4.38
Open
$4.36
Day's High
$4.51
Day's Low
$4.29
Volume
36,977
Avg. Vol
128,736
52-wk High
$12.50
52-wk Low
$4.02

Latest Key Developments (Source: Significant Developments)

Arbutus Biopharma Q2 Earnings Per Share $0.01
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS REPORTS 2018 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 EARNINGS PER SHARE $0.01.Q2 REVENUE $1.2 MILLION VERSUS $1.0 MILLION.Q2 REVENUE VIEW $350,000 -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.40 -- THOMSON REUTERS I/B/E/S.PHASE 1A/1B STUDY OF AB-452, A NOVEL AND PROPRIETARY ORAL RNA DESTABILIZER, EXPECTED TO BEGIN IN SECOND HALF OF 2018.ALL ORAL COMBINATION PHASE 2 STUDY OF AB-506 AND AB-452 EXPECTED TO BEGIN BY END OF 2019.PHASE 1A/1B STUDY OF AB-506, A SECOND-GENERATION ORAL CAPSID INHIBITOR, INITIATED.  Full Article

Arbutus Presents Corporate Update On Key Milestones
Tuesday, 10 Jul 2018 

July 10 (Reuters) - Arbutus Biopharma Corp ::ARBUTUS PRESENTS CORPORATE UPDATE ON KEY MILESTONES.ARBUTUS BIOPHARMA CORP - ALL-ORAL COMBINATION STUDY OF AB-506 AND AB-452 EXPECTED IN 2019.ARBUTUS BIOPHARMA CORP - HBSAG REDUCTION DATA FROM ARB-1467 EXPECTED IN Q4.ARBUTUS BIOPHARMA CORP - ARBUTUS SPINOUT GENEVANT ENTERS PARTNERSHIP WITH MRNA THERAPEUTICS COMPANY BIONTECH.ARBUTUS BIOPHARMA CORP - TOPLINE RESULTS OF AB-506 AND AB-452 ARE EXPECTED BY Q2 2019.ARBUTUS BIOPHARMA CORP - PDUFA DATE FOR PATISIRAN SET FOR AUGUST 11, 2018.  Full Article

Arbutus’ LNP licensee Alnylam initiates rolling submission of NDA for Patisiran
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Arbutus Biopharma Corp ::Arbutus’ LNP licensee Alnylam initiates rolling submission of New Drug Application (NDA) to U.S. Food and drug Administration (fda) for Patisiran.Says Alnylam expects to submit final clinical data for Patisiran by year end ​.  Full Article

Arbutus Biopharma reports Q3 loss per share $0.21
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Arbutus Biopharma Corp :Arbutus Biopharma Corp announces corporate update and third quarter 2017 financial results.Q3 non-GAAP loss per share $0.17.Q3 loss per share $0.21.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.  Full Article

Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Arbutus Biopharma Corp : :Gritstone Oncology and Arbutus Biopharma announce LNP technology licensing agreement to develop novel RNA-based personalized neoantigen immunotherapies for cancer patients.Arbutus Biopharma Corp - is deploying proprietary lipid nanoparticle technology to deliver gritstone's rna-based neoantigen immunotherapy products​.Arbutus Biopharma - ‍under terms of license agreement, gritstone obtains worldwide access to arbutus' portfolio of proprietary and LNP products​.Arbutus Biopharma - ‍Gritstone will pay co upfront payment, payments for achievement of development, regulatory, and commercial milestones.  Full Article

Arbutus provides additional data from the ARB-1467 phase II clinical trial in HBV patients
Monday, 12 Dec 2016 

Arbutus Biopharma Corp : Arbutus Biopharma - one patient in cohort 2 discontinued treatment due to transient elevation of transaminases with normal bilirubin observed . Arbutus Biopharma Corp - company plans to add another cohort to ARB-1467 study to explore bi-weekly administration of 0.4 mg/kg dose . Arbutus Biopharma Corp - complete cohort 1 and 2 ARB-1467 multi-dose data demonstrate dose-responsive hbsag reductions . Arbutus Biopharma Corp - treatment with arb-1467 has been generally well tolerated in this study to date .Arbutus provides additional data from the ARB-1467 phase ii clinical trial in HBV patients.  Full Article

UPDATE 1-Alnylam's gene silencing drug wins FDA approval

Aug 10 Alnylam Pharmaceuticals Inc's drug for a rare hereditary disease won U.S. regulatory approval on Friday, becoming the first approved treatment from a new class of medicines that use gene silencing technology.